Table 1 Risk factors for TMP/SMX treatment failure in PCP infected non-HIV immunocompromised patients by univariate analysis and multivariate analysis
Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
Parameters | Failure, n = 116 | Success, n = 93 | P value | P value | OR | 95% CI |
Demographic information | ||||||
Male, n (%) | 55 (47) | 52 (56) | 0.222 | |||
Age, yr (range) | 55 (44–65) | 50 (31–62) | 0.011 | |||
Underlying disease | ||||||
RID, n (%) | 77 (61) | 46 (44) | 0.009 | |||
Hematologic tumor, n (%) | 8 (6.4) | 6 (5.7) | 0.840 | |||
Solid tumor, n (%) | 6 (4.8) | 4 (3.8) | 0.976 | |||
Organ transplant, n (%) | 6 (4.8) | 1 (1) | 0.199 | |||
Other disease, n (%) | 32 (25) | 47 (45) | 0.002 | |||
TS, n (%) | 107 (85) | 78 (74) | 0.044 | 0.034 | 0.356 | 0.138–0.923 |
Lab examination | ||||||
WBC, × 10.9/L [IQR] | 8.2 [6.4] | 8 [5.5] | 0.814 | |||
LY, × 10.9/L [IQR] | 0.5 [0.6] | 0.8 [0.8] | 0.001 | |||
LDH, U/L [IQR] | 577 [330] | 447 [275] | < 0.001 | |||
BDG, pg/ml [IQR] | 571 [1510] | 750 [1006] | 0.362 | |||
Treatment | ||||||
Sufficient steroid, n (%) | 70 (56) | 57 (54) | 0.847 | |||
Steroid course > 3 m, n (%) | 81 (64) | 68 (65) | 0.940 | |||
Immunosuppressant, n (%) | 97 (77) | 85 (81) | 0.463 | |||
Preventive TMP/SMX, n (%) | 27 (21) | 21 (20) | 0.790 | |||
IMV, n (%) | 84 (67) | 20 (19) | < 0.001 | < 0.001 | 0.222 | 0.103–0.48 |
Co-infection | ||||||
CMV, n (%) | 87 (69) | 49 (47) | 0.001 | 0.035 | 0.464 | 0.227–0.947 |
Bacteremia, n (%) | 74 (59) | 10 (10) | < 0.001 | < 0.001 | 0.148 | 0.060–0.367 |